do glp 1 drugs cause muscle loss Impact of GLP- Receptor Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports Exploring the Side Effects of

Clin Pharmacokinet 56(11):13911401 Vazquez SR (2018) Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

GLP-1 is short for glucagon-like peptide-1

This procedure ensured that individual patients could not be directly or indirectly identified, safeguarding patient privacy in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations

Secondary Research Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research

doi: 10.1111/dom.v22.11 59 MeekerRBWilliamsKKillebrewDAHudsonLC

Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia